Anna Skowron, the Interim Chief Financial Officer of GridAI Technologies Corp., has made significant stock acquisitions, as reported in a recent SEC filing. On October 26, 2026, Skowron acquired 75,000 shares of common stock and 175,000 restricted stock units. This move is notable as it indicates her growing stake in the company and reflects a strong confidence in GridAI's future prospects.

GridAI Technologies Corp. operates in the electric and other services combined sector. The company is incorporated in Delaware and has its business address in Boca Raton, Florida. As of the latest filings, the company has undergone several name changes, previously known as Entero Therapeutics, Inc., First Wave BioPharma, Inc., and AzurRx BioPharma, Inc. The most recent filing was on October 28, 2026, and it was a Form 4.

The SEC filing reveals that Skowron's transactions were part of her role as an officer of the company. Specifically, the filing states, "Represents 75,000 restricted stock units granted on October 26, 2026 under the Issuer's 2020 Omnibus Equity Incentive Plan, as amended." These units were vested as of September 1, 2026, and are settled in shares of common stock. Following these transactions, Skowron now owns a total of 140,000 shares of common stock.

This update may have implications for various stakeholders, including current and potential investors, employees, and competitors within the electric and other services industry. Skowron's increased ownership can be seen as a positive signal, potentially influencing investor sentiment and company morale. Furthermore, other executives in the industry may take similar actions to align their interests with those of shareholders, especially in a competitive market.

As for what’s next, the filing does not specify any forthcoming actions or events related to these transactions. Stakeholders will be watching closely for any additional updates from GridAI Technologies Corp. regarding its financial performance and strategic direction.